Functions of the Tumor Suppressors p53 and Rb in Actin Cytoskeleton Remodeling

por Ebata, Takahiro, Hirata, Hiroaki, Kawauchi, Keiko
Publicado 2016

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma

por Sakaida, Emiko, Ebata, Takahiro, Iwasawa, Shunichiro, Kurimoto, Ryota, Yonemori, Sachiko, Ota, Satoshi, Nakatani, Yukio, Sekine, Ikuo, Takiguchi, Yuichi
Publicado 2017

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation

por KURIMOTO, RYOTA, IWASAWA, SHUNICHIRO, EBATA, TAKAHIRO, ISHIWATA, TSUKASA, SEKINE, IKUO, TADA, YUJI, TATSUMI, KOICHIRO, KOIDE, SHUHEI, IWAMA, ATSUSHI, TAKIGUCHI, YUICHI
Publicado 2016

Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)

por Ishiwata, Tsukasa, Ebata, Takahiro, Iwasawa, Shunichiro, Matsushima, Jun, Ota, Satoshi, Nakatani, Yukio, Tsushima, Kenji, Tada, Yuji, Tatsumi, Koichiro, Takiguchi, Yuichi
Publicado 2017

Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis

por Ebata, Takahiro, Okuma, Yusuke, Nakahara, Yoshiro, Yomota, Makiko, Takagi, Yusuke, Hosomi, Yukio, Asami, Eichi, Omuro, Yasushi, Hishima, Tsunekazu, Okamura, Tatsuru, Takiguchi, Yuichi
Publicado 2015

Substrate Stiffness Influences Doxorubicin-Induced p53 Activation via ROCK2 Expression

por Ebata, Takahiro, Mitsui, Yasumasa, Sugimoto, Wataru, Maeda, Miho, Araki, Keigo, Machiyama, Hiroaki, Harada, Ichiro, Sawada, Yasuhiro, Fujita, Hideaki, Hirata, Hiroaki, Kawauchi, Keiko
Publicado 2017

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

por Kitano, Shigehisa, Shimizu, Toshio, Koyama, Takafumi, Ebata, Takahiro, Iwasa, Satoru, Kondo, Shunsuke, Shimomura, Akihiko, Fujiwara, Yutaka, Yamamoto, Noboru, Paccaly, Anne, Li, Siyu, Rietschel, Petra, Sims, Tasha
Publicado 2020

DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death

por Itoh, Katsuhiko, Ebata, Takahiro, Hirata, Hiroaki, Torii, Takeru, Sugimoto, Wataru, Onodera, Keigo, Nakajima, Wataru, Uehara, Ikuno, Okuzaki, Daisuke, Yamauchi, Shota, Budirahardja, Yemima, Nishikata, Takahito, Tanaka, Nobuyuki, Kawauchi, Keiko
Publicado 2019

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with...

por Ebata, Takahiro, Shimizu, Toshio, Fujiwara, Yutaka, Tamura, Kenji, Kondo, Shunsuke, Iwasa, Satoru, Yonemori, Kan, Shimomura, Akihiko, Kitano, Shigehisa, Koyama, Takafumi, Sato, Natsuko, Nakai, Kiyohiko, Inatani, Michiyasu, Yamamoto, Noboru
Publicado 2019